ORMP
Oramed Pharmaceuticals Inc.Healthcare·Biotechnology
$3.97
$162M market cap
Revenue
$0.0M
Free Cash Flow
$-3.2M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical tr
2-Year Price History
$3.99+103.6%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | 0.0 | 0.0 | 38.3 | -2.9 | -2.9 | -0.0 | 65.8 | 0.8 | 42.0 | 0.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | 9.8 | -5.7 | 10.0 | -0.5 | -0.3 | -0.2 | 125.9 | 0.8 | 42.4 | -33.2% | -- | -- |
Valuation & Metrics
Market Stats
Price$3.97
Market Cap$162M
Enterprise Value$97M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-2.0%
Dividend Yield (TTM)6.3%
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$48.3M
Free Cash Flow$-3.2M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-16.6%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.7M
Days to Cover4.5
Change (vs Prior)+12.8%
Need at least 2 settlement dates for chart
Employees
Headcount13
Revenue / Employee$0
Gross Profit / Employee$0
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
24.5%(+15.7% YoY)
59 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.5%(+0.1% YoY)
3 filers
Vanguard, iShares, SPDR
Market makers
0.4%(+0.1% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| BML Capital Management, LLC | $10.8M | $2.17 | +$0 | +$498K | -1.1% | $155M |
| Aquamarine Financial (Cayman) Ltd | $7.2M | $2.52 | +$473K | +$7.2M | +18.9% | $1.37B |
| MERCER GLOBAL ADVISORS INC /ADV | $6.5M | $3.40 | +$6.5M | +$6.5M | -0.0% | $63.93B |
| Gem Investment Advisors, LLC | $5.6M | $2.66 | −$1.2M | +$5.6M | +3.9% | $102M |
| Murchinson Ltd. | $4.5M | $2.31 | −$85K | −$1.5M | -1.5% | $249M |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.0M | $2.31 | −$39K | −$832K | -0.4% | $4.25B |
| MARSHALL WACE, LLP | $883K | $3.08 | +$2K | +$883K | +0.6% | $92.71B |
| Rathbones Group PLC | $792K | $2.43 | +$0 | −$13K | -0.4% | $23.41B |
| DIMENSIONAL FUND ADVISORS LPPassive | $538K | $2.30 | +$26K | +$58K | -0.4% | $480.92B |
| WELLS FARGO & COMPANY/MN | $536K | $3.68 | +$92K | +$464K | -0.2% | $497.71B |
| RITHOLTZ WEALTH MANAGEMENT | $529K | $3.40 | +$529K | +$529K | +0.2% | $5.76B |
| RENAISSANCE TECHNOLOGIES LLC | $502K | $2.79 | +$0 | +$18K | +1.2% | $63.91B |
| BANK OF AMERICA CORP /DE/ | $497K | $2.19 | +$13K | −$60K | -0.1% | $1.36T |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $463K | $3.46 | +$375K | +$122K | -0.6% | $77.14B |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $396K | $3.40 | +$395K | +$396K | — | $19.92B |
| CITADEL ADVISORS LLC | $335K | $3.61 | −$331K | +$335K | -0.4% | $138.22B |
| Hillsdale Investment Management Inc. | $331K | $3.40 | +$331K | +$331K | +0.3% | $3.68B |
| BlackRock, Inc.Passive | $313K | $2.33 | +$7K | −$0 | -0.2% | $5.69T |
| JANE STREET GROUP, LLCMM | $179K | $5.53 | −$87K | −$50K | -0.1% | $92.10B |
| Hudson Bay Capital Management LP | $176K | $3.40 | +$176K | +$176K | +1.9% | $15.12B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+3.32%
avg per quarter
Holders (ex-self)
+3.26%
excl. this stock
Buyers (this Q)
+2.82%
32 buyers · $0.01B in
Sellers (this Q)
-3.42%
19 sellers · $-0.00B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-3.9%
how holders react when this stock falls
On quiet Qs
-27.8%
−10% to +10% baseline
On rallies (+10%+)
-11.1%
how they react when this stock rises
Holders' portfolio flow this Q
+8.1%
inflows — adds are organic
Sellers' portfolio flow this Q
+66.9%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.2%
Holder mid (any stock)
-1.6%
Holder rally (any stock)
-7.6%
Biggest decreases this quarter
Gem Investment Advisors, LLC−$1.2Mα+3.9CITADEL ADVISORS LLC−$331Kα-0.4Squarepoint Ops LLCexited−$166KRBF Capital, LLCexited−$122KQuadrature Capital Ltdexited−$119KJANE STREET GROUP, LLC−$87Kα-0.1Murchinson Ltd.−$85Kα-1.5TWO SIGMA SECURITIES, LLCexited−$66KHRT FINANCIAL LP−$63Kα-0.6BOOTHBAY FUND MANAGEMENT, LLC−$39Kα-0.4
New buyers this quarter
Top-5 holders · 76.6%
BML Capital Management, LLC--
Aquamarine Financial (Cayman) Ltd--
MERCER GLOBAL ADVISORS INC /ADV--
Gem Investment Advisors, LLC--
Murchinson Ltd.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Invesco Ltd.—Altium Capital Management LP—MILLENNIUM MANAGEMENT LLC16KBML Capital Management, LLC3.2MCITADEL ADVISORS LLC99KAquamarine Financial (Cayman) Ltd2.1MMERCER GLOBAL ADVISORS INC /ADV1.9MTWO SIGMA INVESTMENTS, LP—TWO SIGMA ADVISERS, LP—Gem Investment Advisors, LLC1.6M
Analyst Coverage
Analyst Coverage
Analyst Ratings
6
2
Buy: 6Hold: 2Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
30.5%retail-7.5pp
13.1%dark+0.6pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Oramed Pharmaceuticals: A Strategic Hedge Fund Masquerading as Biotech with Aggressive Level 3 Valuations
Overall Risk
7/10
Fraud
5/10
Dilution
4/10
Insolvency
2/10
Earnings Overstated
9/10
Hidden Liabilities
5/10
Legal
4/10
Audit Warnings
6/10
Hidden Upside
4/10
Contextually Acceptable
3/10